Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.
2.

Treatments of uremic pruritus: A systematic review.

Malekmakan L, Tadayon T, Pakfetrat M, Mansourian A, Zareei N.

Dermatol Ther. 2018 Sep;31(5):e12683. doi: 10.1111/dth.12683. Epub 2018 Aug 23. Review.

PMID:
30141218
3.

Acute interstitial nephritis in the south of Iran; an observational study.

Khodamoradi Z, Pakfetrat M, Torabinezhad S, Sagheb MM.

J Nephropathol. 2017 Jul;6(3):225-230. doi: 10.15171/jnp.2017.37. Epub 2017 Apr 20.

4.

A comparison of socioeconomic level among hemodialysis patients and normal controls in the fars province, Iran.

Malekmakan L, Pakfetrat M, Daneshian A, Sayadi M.

Saudi J Kidney Dis Transpl. 2017 Sep-Oct;28(5):1138-1143. doi: 10.4103/1319-2442.215131.

5.

Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran.

Pakfetrat M, Malekmakan L, Hashemi N, Tadayon T.

Hemodial Int. 2018 Jan;22(1):103-109. doi: 10.1111/hdi.12540. Epub 2017 Mar 6.

PMID:
28263039
6.

Therapeutic Effect of Montelukast for Treatment of Uremic Pruritus in Hemodialysis Patients.

Mahmudpour M, Roozbeh J, Raiss Jalali GA, Pakfetrat M, Ezzat Zadegan S, Sagheb MM.

Iran J Kidney Dis. 2017 Jan;11(1):50-55.

7.

Prevalence of hypothyroidism and thyroid nodule in chronic hemodialysis Iranian patients.

Pakfetrat M, Dabbaghmanesh MH, Karimi Z, Rasekhi A, Malekmakan L, Hossein Nikoo M.

Hemodial Int. 2017 Jan;21(1):84-89. doi: 10.1111/hdi.12453. Epub 2016 Jun 30.

PMID:
27364542
8.

Hypertension and diabetes remain the main causes of chronic renal failure in Fars Province, Iran 2013.

Malekmakan L, Malekmakan A, Daneshian A, Pakfetrat M, Roosbeh J.

Saudi J Kidney Dis Transpl. 2016 Mar;27(2):423-4. doi: 10.4103/1319-2442.178594. No abstract available.

9.

Association of high-sensitive C-reactive protein and dialysis adequacy with uremic pruritus.

Malekmakan L, Malekmakan A, Sayadi M, Pakfetrat M, Sepaskhah M, Roozbeh J.

Saudi J Kidney Dis Transpl. 2015 Sep;26(5):890-5. doi: 10.4103/1319-2442.164565.

10.

Role of turmeric in oxidative modulation in end-stage renal disease patients.

Pakfetrat M, Akmali M, Malekmakan L, Dabaghimanesh M, Khorsand M.

Hemodial Int. 2015 Jan;19(1):124-31. doi: 10.1111/hdi.12204. Epub 2014 Aug 16.

PMID:
25131305
11.

Prevalence of chronic kidney disease and its contributing risk factors in southern Iran: a cross-sectional adult population-based study.

Khajehdehi P, Malekmakan L, Pakfetrat M, Roozbeh J, Sayadi M.

Iran J Kidney Dis. 2014 Mar;8(2):109-15.

12.

Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial.

Pakfetrat M, Basiri F, Malekmakan L, Roozbeh J.

J Nephrol. 2014 Apr;27(2):203-7. doi: 10.1007/s40620-014-0039-2. Epub 2014 Jan 31.

PMID:
24482090
13.

Stone composition in patients who undergo renal stone surgery: review of 423 stone analyses in southern iran.

Hosseini MM, Shakeri S, Manaheji F, Aminsharifi A, Ezatzadegan S, Pakfetrat M, Basiratnia M, Hosseini M.

Iran J Med Sci. 2014 Jan;39(1):75-6. No abstract available.

14.

Ergotamine-induced acute tubulo-interstitial nephritis.

Pakfetrat M, Rasekhi A, Eftekhari F, Hashemi N, Roozbeh J, Torabineghad S, Malekmakan L.

Saudi J Kidney Dis Transpl. 2013 Sep;24(5):981-3.

15.

The preventive effect of pentoxifylline on contrast-induced nephropathy: a randomized clinical trial.

Yavari V, Ostovan MA, Kojuri J, Afshariani R, Hamidian Jahromi A, Roozbeh J, Pakfetrat M.

Int Urol Nephrol. 2014 Jan;46(1):41-6. doi: 10.1007/s11255-013-0420-4. Epub 2013 Apr 10. Erratum in: Int Urol Nephrol. 2014 Jan;46(1):47. Hamidian, Alireza [corrected to Hamidian Jahromi, Alireza].

PMID:
23572413
16.

Effects of zinc supplement on plasma homocysteine level in end-stage renal disease patients: a double-blind randomized clinical trial.

Pakfetrat M, Shahroodi JR, Zolgadr AA, Larie HA, Nikoo MH, Malekmakan L.

Biol Trace Elem Res. 2013 Jun;153(1-3):11-5. doi: 10.1007/s12011-013-9639-2. Epub 2013 Mar 12.

PMID:
23475369
17.

Application of seemingly unrelated regression in medical data with intermittently observed time-dependent covariates.

Keshavarzi S, Ayatollahi SM, Zare N, Pakfetrat M.

Comput Math Methods Med. 2012;2012:821643. doi: 10.1155/2012/821643. Epub 2012 Dec 18.

18.

Prevalence of chronic kidney disease and its related risk factors in elderly of southern iran: a population-based study.

Malekmakan L, Khajehdehi P, Pakfetrat M, Malekmakan A, Mahdaviazad H, Roozbeh J.

ISRN Nephrol. 2013 Jul 7;2013:427230. doi: 10.5402/2013/427230. eCollection 2013.

19.

Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.

Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.

Am J Kidney Dis. 2012 Dec;60(6):896-903. doi: 10.1053/j.ajkd.2012.06.005. Epub 2012 Jul 7.

PMID:
22770926
20.

Cloxacillin as an antibiotic lock solution for prevention of catheter-associated infection.

Davanipur M, Pakfetrat M, Roozbeh J.

Iran J Kidney Dis. 2011 Sep;5(5):328-31.

21.

Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.

Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, Dehghanzadeh G.

Scand J Urol Nephrol. 2011 Nov;45(5):365-70. doi: 10.3109/00365599.2011.585622. Epub 2011 May 31.

PMID:
21627399
22.

Comment on: does zinc supplementation affect inflammatory markers in hemodialysis patients?

Roozbeh J, Sharifian M, Sagheb MM, Shabani S, Hamidian Jahromi A, Afshariani R, Pakfetrat M, Salehi O.

Ren Fail. 2011;33(4):466-7. doi: 10.3109/0886022X.2011.568144. No abstract available.

PMID:
21529280
23.

Epidemiology of erectile dysfunction in hemodialysis patients using IIEF questionnaire.

Malekmakan L, Shakeri S, Haghpanah S, Pakfetrat M, Sarvestani AS, Malekmakan A.

Saudi J Kidney Dis Transpl. 2011 Mar;22(2):232-6.

24.

Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis.

Roozbeh J, Shahriyari B, Akmali M, Vessal G, Pakfetrat M, Raees Jalali GA, Afshariani R, Hasheminasab M, Ghahramani N.

Ren Fail. 2011;33(2):118-23. doi: 10.3109/0886022X.2010.541579.

25.

Is there an association between intradialytic hypotension and serum magnesium changes?

Pakfetrat M, Roozbeh Shahroodi J, Malekmakan L, Zare N, Hashemi Nasab M, Hossein Nikoo M.

Hemodial Int. 2010 Oct;14(4):492-7. doi: 10.1111/j.1542-4758.2010.00477.x.

PMID:
20955283
26.

Comparison of risk factors for contrast-induced acute kidney injury between patients with and without diabetes.

Pakfetrat M, Nikoo MH, Malekmakan L, Tabande M, Roozbeh J, Ganbar Ali RJ, Khajehdehi P.

Hemodial Int. 2010 Oct;14(4):387-92. doi: 10.1111/j.1542-4758.2010.00469.x. Epub 2010 Aug 27.

PMID:
20796046
27.

Relation of serum albumin and C-reactive protein to hypotensive episodes during hemodialysis sessions.

Pakfetrat M, Roozbeh J, Malekmakan L, Zare N, Nasab MH, Nikoo MH.

Saudi J Kidney Dis Transpl. 2010 Jul;21(4):707-11.

28.

Risk Factors for contrast-related acute kidney injury according to risk, injury, failure, loss, and end-stage criteria in patients with coronary interventions.

Pakfetrat M, Nikoo MH, Malekmakan L, Tabande M, Roozbeh J, Reisjalali G, Zare N, Khajedehi P.

Iran J Kidney Dis. 2010 Apr;4(2):116-22.

29.

Dialysis adequacy and Kidney Disease Outcomes Quality Initiative goals achievement in an Iranian hemodialysis population.

Malekmakan L, Haghpanah S, Pakfetrat M, Malekmakan A, Alimanesh M, Haghpanah A, Khajedehi P.

Iran J Kidney Dis. 2010 Jan;4(1):39-43.

30.

Diminished selenium levels in hemodialysis and continuous ambulatory peritoneal dialysis patients.

Pakfetrat M, Malekmakan L, Hasheminasab M.

Biol Trace Elem Res. 2010 Dec;137(3):335-9. doi: 10.1007/s12011-009-8588-2. Epub 2009 Dec 29.

PMID:
20039146
31.

Causes of chronic renal failure among Iranian hemodialysis patients.

Malekmakan L, Haghpanah S, Pakfetrat M, Malekmakan A, Khajehdehi P.

Saudi J Kidney Dis Transpl. 2009 May;20(3):501-4.

32.

Tuberculosis in a kidney transplant recipient diagnosed by fine needle aspiration cytology of the bone marrow.

Azarpira N, Pakfetrat M.

Saudi J Kidney Dis Transpl. 2009 May;20(3):482-3. No abstract available.

33.

A comparison of sodium bicarbonate infusion versus normal saline infusion and its combination with oral acetazolamide for prevention of contrast-induced nephropathy: a randomized, double-blind trial.

Pakfetrat M, Nikoo MH, Malekmakan L, Tabandeh M, Roozbeh J, Nasab MH, Ostovan MA, Salari S, Kafi M, Vaziri NM, Adl F, Hosseini M, Khajehdehi P.

Int Urol Nephrol. 2009;41(3):629-34. doi: 10.1007/s11255-008-9520-y. Epub 2009 Jan 10.

PMID:
19137409
34.

Magnesium and its relationship to C-reactive protein among hemodialysis patients.

Pakfetrat M, Malekmakan L, Roozbeh J, Haghpanah S.

Magnes Res. 2008 Sep;21(3):167-70.

35.

Protective effect of pentoxifylline on contrast induced nephropathy.

Roozbeh J, Hamidian Jahromi A, Sharifian M, Pakfetrat M, Afshariani R.

Saudi J Kidney Dis Transpl. 2008 Nov;19(6):985-6. No abstract available.

Supplemental Content

Loading ...
Support Center